{"transactions":[{"id":884482,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-02-24T23:41:39.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":12050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":12050,"derivative":{"exercise_price":17.64,"expiration_date":"2036-02-20","underlying":"Common Stock","underlying_shares":12050},"source":{"system":"sec-edgar","filing":"0001274826-26-000002","document":"wk-form4_1771976497.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000127482626000002/wk-form4_1771976497.xml","form_type":"4"}},{"id":1111414,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-06-13T16:07:42.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":12050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the total shares monthly beginning July 12, 2025 until the option is fully vested on June 12, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":12050,"derivative":{"exercise_price":20.4,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":12050},"source":{"system":"sec-edgar","filing":"0001404644-25-000068","document":"wk-form4_1749830856.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464425000068/wk-form4_1749830856.xml","form_type":"4"}},{"id":1477158,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T18:36:28.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":7700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 7,700 shares of the Issuer's common stock, which will vest in its entirety on the earlier of (a) the first anniversary of the date of grant or (b) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such applicable vesting date."}],"balance_after":7700,"derivative":{"exercise_price":42.59,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":7700},"source":{"system":"sec-edgar","filing":"0001404644-24-000069","document":"wk-form4_1718649381.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000069/wk-form4_1718649381.xml","form_type":"4"}},{"id":1676216,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-18T23:51:00.000Z","date":"2024-01-16","kind":"grant","planned":false,"acquired":true,"shares":15400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 15,400 shares of common stock of the Issuer, and vests in equal monthly installments through January 16, 2027, subject to the reporting person's continued service to the Issuer through each applicable vesting date."}],"balance_after":15400,"derivative":{"exercise_price":32.3,"expiration_date":"2034-01-16","underlying":"Common Stock","underlying_shares":15400},"source":{"system":"sec-edgar","filing":"0000950170-24-005533","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000095017024005533/ownership.xml","form_type":"4"}},{"id":2383645,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Note","published_at":"2022-02-23T00:55:16.000Z","date":"2022-02-18","kind":"other","acquired":true,"price":50000,"reported_value":50000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $50,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $50,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $50,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $50,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."}],"derivative":{"underlying":"See footnotes"},"source":{"system":"sec-edgar","filing":"0001683168-22-001211","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316822001211/ownership.xml","form_type":"4"}},{"id":3196814,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Mfg/Tech Ops"}}],"security":"Common Stock","published_at":"2020-03-25T00:57:27.000Z","date":"2020-03-20","kind":"tax_withholding","acquired":false,"shares":3501,"price":73.05,"value":255748.05,"ownership":{"direct":true},"balance_after":117138,"source":{"system":"sec-edgar","filing":"0001567619-20-006972","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761920006972/doc1.xml","form_type":"4"}},{"id":3206283,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Mfg/Tech Ops"}}],"security":"Stock Option (Right to buy Common Stock)","published_at":"2020-03-18T01:11:24.000Z","date":"2020-03-16","kind":"grant","acquired":true,"shares":30390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"Option grant vests 12/48th on March 16, 2021 and 1/48th on the 16th day of each month thereafter."}],"balance_after":30390,"derivative":{"exercise_price":73.82,"exercise_date":"2021-03-16","expiration_date":"2030-03-15","underlying":"Common Stock","underlying_shares":30390},"source":{"system":"sec-edgar","filing":"0001567619-20-006630","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761920006630/doc1.xml","form_type":"4"}},{"id":3206282,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Mfg/Tech Ops"}}],"security":"Common Stock","published_at":"2020-03-18T01:11:24.000Z","date":"2020-03-16","kind":"grant","acquired":true,"shares":10660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on March 16, 2020. Price not applicable."}],"balance_after":120639,"source":{"system":"sec-edgar","filing":"0001567619-20-006630","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761920006630/doc1.xml","form_type":"4"}},{"id":3206281,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Mfg/Tech Ops"}}],"security":"Common Stock","published_at":"2020-03-18T01:11:24.000Z","date":"2020-03-13","kind":"tax_withholding","acquired":false,"shares":7600,"price":84.5,"value":642200.0,"ownership":{"direct":true},"balance_after":109979,"source":{"system":"sec-edgar","filing":"0001567619-20-006630","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761920006630/doc1.xml","form_type":"4"}},{"id":3228468,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Mfg/Tech Ops"}}],"security":"Common Stock","published_at":"2020-03-05T02:41:52.000Z","date":"2020-03-03","kind":"grant","acquired":true,"shares":9852,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2019 as set forth in the Issuer's audited financial statements."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 15, 2020, 2021 and 2022, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events."}],"balance_after":117579,"source":{"system":"sec-edgar","filing":"0001567619-20-005675","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761920005675/doc1.xml","form_type":"4"}},{"id":3496078,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Mfg/Tech Ops"}}],"security":"Common Stock","published_at":"2019-06-10T23:03:33.000Z","date":"2019-04-30","kind":"grant","acquired":true,"shares":309,"price":68.782,"value":21253.638,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents shares acquired by the reporting person on April 30, 2019, pursuant to the issuer's Employee Stock Purchase Plan."}],"balance_after":107727,"source":{"system":"sec-edgar","filing":"0001567619-19-013182","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919013182/doc1.xml","form_type":"4"}},{"id":3499211,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Global Mfg/Tech Ops"}}],"security":"Common Stock","published_at":"2019-06-06T21:07:23.000Z","date":"2019-06-05","kind":"grant","acquired":true,"shares":14160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on June 5, 2019. Price not applicable."}],"balance_after":107418,"source":{"system":"sec-edgar","filing":"0001567619-19-012952","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919012952/doc1.xml","form_type":"4"}},{"id":3578837,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2019-03-27T00:44:09.000Z","date":"2019-03-22","kind":"tax_withholding","acquired":false,"shares":3501,"price":88.05,"value":308263.05,"ownership":{"direct":true},"balance_after":93258,"source":{"system":"sec-edgar","filing":"0001567619-19-007690","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919007690/doc1.xml","form_type":"4"}},{"id":3588327,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Stock Option (Right to buy Common Stock)","published_at":"2019-03-19T22:55:53.000Z","date":"2019-03-15","kind":"grant","acquired":true,"shares":24120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"Option grant vests 12/48th on March 15, 2020 and 1/48th on the 15th day of each month thereafter."}],"balance_after":24120,"derivative":{"exercise_price":94.53,"exercise_date":"2020-03-15","expiration_date":"2029-03-14","underlying":"Common Stock","underlying_shares":24120},"source":{"system":"sec-edgar","filing":"0001567619-19-007245","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919007245/doc1.xml","form_type":"4"}},{"id":3588326,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2019-03-19T22:55:53.000Z","date":"2019-03-15","kind":"grant","acquired":true,"shares":9630,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on March 15, 2019. Price not applicable."}],"balance_after":96759,"source":{"system":"sec-edgar","filing":"0001567619-19-007245","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919007245/doc1.xml","form_type":"4"}},{"id":3588325,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2019-03-19T22:55:53.000Z","date":"2019-03-15","kind":"tax_withholding","acquired":false,"shares":7083,"price":94.53,"value":669555.99,"ownership":{"direct":true},"balance_after":87129,"source":{"system":"sec-edgar","filing":"0001567619-19-007245","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919007245/doc1.xml","form_type":"4"}},{"id":3614454,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2019-03-06T00:28:15.000Z","date":"2019-03-01","kind":"tax_withholding","acquired":false,"shares":917,"price":94.76,"value":86894.92,"ownership":{"direct":true},"balance_after":94212,"source":{"system":"sec-edgar","filing":"0001567619-19-006231","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919006231/doc1.xml","form_type":"4"}},{"id":3614453,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2019-03-06T00:28:15.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":11853,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2018 as set forth in the Issuer's audited financial statements."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 15, 2019, 2020 and 2021, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events."}],"balance_after":95129,"source":{"system":"sec-edgar","filing":"0001567619-19-006231","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919006231/doc1.xml","form_type":"4"}},{"id":3848794,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2018-08-09T20:58:32.000Z","date":"2018-08-07","kind":"sale","acquired":false,"shares":5173,"price":105,"value":543165.0,"ownership":{"direct":false,"nature":"Shares held by Baffi Family Trust"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on September 12, 2017."}],"balance_after":71882,"source":{"system":"sec-edgar","filing":"0001567619-18-000257","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761918000257/doc1.xml","form_type":"4"}},{"id":3883369,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Stock Option (Right to buy Common Stock)","published_at":"2018-06-27T00:23:49.000Z","date":"2018-06-22","kind":"exercise","acquired":false,"shares":6949,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on March 6, 2018."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the number of options outstanding after the transactions from this specific stock option grant."}],"balance_after":0,"derivative":{"exercise_price":14.39,"exercise_date":"2009-11-12","expiration_date":"2019-05-11","underlying":"Common Stock","underlying_shares":6949},"source":{"system":"sec-edgar","filing":"0001140361-18-030008","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118030008/doc1.xml","form_type":"4"}},{"id":3883368,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2018-06-27T00:23:49.000Z","date":"2018-06-22","kind":"sale","acquired":false,"shares":328,"price":99.01,"value":32475.28,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on March 6, 2018."}],"balance_after":83276,"source":{"system":"sec-edgar","filing":"0001140361-18-030008","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118030008/doc1.xml","form_type":"4"}},{"id":3883367,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2018-06-27T00:23:49.000Z","date":"2018-06-22","kind":"sale","acquired":false,"shares":6621,"price":99,"value":655479.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on March 6, 2018."}],"balance_after":83604,"source":{"system":"sec-edgar","filing":"0001140361-18-030008","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118030008/doc1.xml","form_type":"4"}},{"id":3883366,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2018-06-27T00:23:49.000Z","date":"2018-06-22","kind":"exercise","acquired":true,"shares":6949,"price":14.39,"value":99996.11,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on March 6, 2018."}],"balance_after":90225,"source":{"system":"sec-edgar","filing":"0001140361-18-030008","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118030008/doc1.xml","form_type":"4"}},{"id":3903753,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2018-06-07T00:01:30.000Z","date":"2018-06-04","kind":"tax_withholding","acquired":false,"shares":1562,"price":92.07,"value":143813.34,"ownership":{"direct":true},"balance_after":83276,"source":{"system":"sec-edgar","filing":"0001140361-18-027599","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118027599/doc1.xml","form_type":"4"}},{"id":3903752,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2018-06-07T00:01:30.000Z","date":"2018-04-30","kind":"grant","acquired":true,"shares":309,"price":68.782,"value":21253.638,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents shares acquired by the reporting person on April 30, 2018, pursuant to the issuer's Employee Stock Purchase Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount of securities beneficially owned has been adjusted from the reporting person's prior report to: a) add 84 shares reported as acquired in the Form 4 Amendment filed with the S.E.C. on 4/26/2018; and b) subtract 14 shares reported as disposed of in the Form 4 Amendment filed with the S.E.C. on 4/27/2018."}],"balance_after":84838,"source":{"system":"sec-edgar","filing":"0001140361-18-027599","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118027599/doc1.xml","form_type":"4"}},{"id":3955185,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2018-04-27T22:47:18.000Z","date":"2018-03-22","kind":"tax_withholding","acquired":false,"shares":3500,"price":81.36,"value":284760.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This amendment is being filed solely to correct an administrative error in the original filing regarding the number of shares reported as forfeited."}],"balance_after":84445,"source":{"system":"sec-edgar","filing":"0001140361-18-020280","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118020280/doc1.xml","form_type":"4/A","original_submission_date":"2018-03-26"}},{"id":3956336,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2018-04-27T00:38:00.000Z","date":"2018-02-26","kind":"grant","acquired":true,"shares":12274,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 22, 2018, 2019 and 2020, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2017 as set forth in the Issuer's audited financial statements."},{"field":"shares","element":"transactionShares","label":"F4","text":"This amendment is being filed solely to correct an administrative error in the original filing regarding the number of RSUs reported as earned."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Amount of securities beneficially owned has been updated from the reporting person's prior report to:  a) exclude 55,663 shares reported in the Form 4 Amendment filed with the S.E.C. on 10/13/2017; and b) exclude 4,526 shares inadvertently included in prior reports based on a reconciliation with the Company's records."}],"balance_after":81168,"source":{"system":"sec-edgar","filing":"0001140361-18-019858","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118019858/doc1.xml","form_type":"4/A","original_submission_date":"2018-02-28"}},{"id":3983254,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2018-03-26T23:45:43.000Z","date":"2018-03-22","kind":"tax_withholding","acquired":false,"shares":3486,"price":81.36,"value":283620.96,"ownership":{"direct":true},"balance_after":84459,"source":{"system":"sec-edgar","filing":"0001140361-18-015069","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118015069/doc1.xml","form_type":"4"}},{"id":3990184,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Stock Option (Right to buy Common Stock)","published_at":"2018-03-20T01:48:30.000Z","date":"2018-03-15","kind":"grant","acquired":true,"shares":38760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option grant vests 12/48th on March 15, 2019 and 1/48th on the 15th day of each month thereafter."}],"balance_after":38760,"derivative":{"exercise_price":83.57,"exercise_date":"2019-03-15","expiration_date":"2028-03-14","underlying":"Common Stock","underlying_shares":38760},"source":{"system":"sec-edgar","filing":"0001140361-18-014188","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118014188/doc1.xml","form_type":"4"}},{"id":3990183,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2018-03-20T01:48:30.000Z","date":"2018-03-15","kind":"grant","acquired":true,"shares":12120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on March 15, 2018.  Price not applicable."}],"balance_after":87945,"source":{"system":"sec-edgar","filing":"0001140361-18-014188","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118014188/doc1.xml","form_type":"4"}},{"id":3990182,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2018-03-20T01:48:30.000Z","date":"2018-03-15","kind":"tax_withholding","acquired":false,"shares":3644,"price":83.57,"value":304529.08,"ownership":{"direct":true},"balance_after":75825,"source":{"system":"sec-edgar","filing":"0001140361-18-014188","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118014188/doc1.xml","form_type":"4"}},{"id":4011922,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2018-03-07T01:33:32.000Z","date":"2018-03-02","kind":"tax_withholding","acquired":false,"shares":1615,"price":79.86,"value":128973.9,"ownership":{"direct":true},"balance_after":79469,"source":{"system":"sec-edgar","filing":"0001140361-18-012364","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118012364/doc1.xml","form_type":"4"}},{"id":4028094,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2018-03-01T01:44:22.000Z","date":"2018-02-26","kind":"grant","acquired":true,"shares":12190,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 22, 2018, 2019 and 2020, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2017 as set forth in the Issuer's audited financial statements."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Amount of securities beneficially owned has been updated from the reporting person's prior report to:  a) exclude 55,663 shares reported in the Form 4 Amendment filed with the S.E.C. on 10/13/2017; and b) exclude 4,526 shares inadvertently included in prior reports based on a reconciliation with the Company's records."}],"balance_after":81084,"source":{"system":"sec-edgar","filing":"0001140361-18-010977","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118010977/doc1.xml","form_type":"4"}},{"id":4186887,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2017-10-13T23:42:08.000Z","date":"2016-03-15","kind":"other","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Shares held by Baffi Family Trust"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On March 17, 2016, the reporting person filed a Form 4 which inadvertently reported an incorrect total amount of securities beneficially owned following the reported transactions.  This amendment corrects such total."}],"balance_after":72102,"source":{"system":"sec-edgar","filing":"0001140361-17-038680","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117038680/doc1.xml","form_type":"4/A","original_submission_date":"2016-03-17"}},{"id":4186886,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2017-10-13T23:42:08.000Z","date":"2016-03-15","kind":"other","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On March 17, 2016, the reporting person filed a Form 4 which inadvertently reported an incorrect total amount of securities beneficially owned following the reported transactions.  This amendment corrects such total."}],"balance_after":82963,"source":{"system":"sec-edgar","filing":"0001140361-17-038680","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117038680/doc1.xml","form_type":"4/A","original_submission_date":"2016-03-17"}},{"id":4198063,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2017-10-03T01:07:08.000Z","date":"2017-09-28","kind":"sale","acquired":false,"shares":2915,"price":92.06,"value":268354.9,"ownership":{"direct":false,"nature":"Shares held by Baffi Family Trust"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on September 12, 2017."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on September 12, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"All shares sold at the same price."}],"balance_after":28761,"source":{"system":"sec-edgar","filing":"0001140361-17-037214","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117037214/doc1.xml","form_type":"4"}},{"id":4198062,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2017-10-03T01:07:08.000Z","date":"2017-09-28","kind":"sale","acquired":false,"shares":15500,"price":92.4952,"value":1433675.6,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on September 12, 2017."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on September 12, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is the weighted average price.  The price actually received ranged from $91.92 to $92.90.  The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price."}],"balance_after":129083,"source":{"system":"sec-edgar","filing":"0001140361-17-037214","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117037214/doc1.xml","form_type":"4"}},{"id":4291530,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2017-06-07T00:45:51.000Z","date":"2017-06-02","kind":"tax_withholding","acquired":false,"shares":1644,"price":90.72,"value":149143.68,"ownership":{"direct":true},"balance_after":144583,"source":{"system":"sec-edgar","filing":"0001140361-17-024242","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117024242/doc1.xml","form_type":"4"}},{"id":4316291,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2017-05-17T22:46:33.000Z","date":"2017-05-15","kind":"tax_withholding","acquired":false,"shares":1566,"price":91.5,"value":143289.0,"ownership":{"direct":true},"balance_after":146227,"source":{"system":"sec-edgar","filing":"0001140361-17-021237","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117021237/doc1.xml","form_type":"4"}},{"id":4316290,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2017-05-17T22:46:33.000Z","date":"2017-04-28","kind":"grant","acquired":true,"shares":302,"price":70.304,"value":21231.808,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents shares acquired by the reporting person pursuant to issuer's Employee Stock Purchase Plan."}],"balance_after":147793,"source":{"system":"sec-edgar","filing":"0001140361-17-021237","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117021237/doc1.xml","form_type":"4"}},{"id":4372772,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Stock Option (Right to buy Common Stock)","published_at":"2017-03-24T22:40:31.000Z","date":"2017-03-22","kind":"grant","acquired":true,"shares":38420,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option grant vests 12/48th on March 22, 2018 and 1/48th on the 22nd day of each month thereafter."}],"balance_after":38420,"derivative":{"exercise_price":87.42,"exercise_date":"2018-03-22","expiration_date":"2027-03-21","underlying":"Common Stock","underlying_shares":38420},"source":{"system":"sec-edgar","filing":"0001140361-17-013313","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117013313/doc1.xml","form_type":"4"}},{"id":4372771,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2017-03-24T22:40:31.000Z","date":"2017-03-22","kind":"grant","acquired":true,"shares":11870,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on March 22, 2017.  Price not applicable."}],"balance_after":147491,"source":{"system":"sec-edgar","filing":"0001140361-17-013313","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117013313/doc1.xml","form_type":"4"}},{"id":4380474,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2017-03-17T22:34:05.000Z","date":"2017-03-15","kind":"tax_withholding","acquired":false,"shares":3289,"price":92.5,"value":304232.5,"ownership":{"direct":true},"balance_after":135621,"source":{"system":"sec-edgar","filing":"0001140361-17-012649","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117012649/doc1.xml","form_type":"4"}},{"id":4398357,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2017-03-07T23:42:49.000Z","date":"2017-03-03","kind":"tax_withholding","acquired":false,"shares":1749,"price":93.95,"value":164318.55,"ownership":{"direct":true},"balance_after":138910,"source":{"system":"sec-edgar","filing":"0001140361-17-010940","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117010940/doc1.xml","form_type":"4"}},{"id":4418461,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Technical Operations"}}],"security":"Common Stock","published_at":"2017-02-28T21:42:50.000Z","date":"2017-02-24","kind":"grant","acquired":true,"shares":11917,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the total number of RSUs earned pursuant to a calculation based on the level of the Issuer's total adjusted revenues for the fiscal year ended December 31, 2016, as certified by its audited financials, set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 15, 2017, 2018 and 2019, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain corporate events."}],"balance_after":140659,"source":{"system":"sec-edgar","filing":"0001140361-17-009678","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117009678/doc1.xml","form_type":"4"}}]}